Related Experiment Video

Updated: Feb 25, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K

The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas

Rolando Ruiz1, Sohail Jahid2, Melissa Harris3

  • 1Department of Biological Chemistry, University of California, Irvine, Irvine, CA, United States of America.

Plos Genetics
|July 29, 2017
PubMed

Insights

Researchers discovered a RhoJ signaling pathway that can be targeted to treat BRAF-mutant melanoma. Inhibiting this pathway halts tumor growth and induces cancer cell death, offering a new therapeutic strategy for BRAF-mutant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Cancer cells develop mechanisms to survive oncogene-induced stress.
  • Identifying these survival pathways is crucial for developing targeted cancer therapies.
  • BRAF mutations are common drivers in melanoma, necessitating specific treatment strategies.

Purpose of the Study:

  • To identify novel therapeutic targets for BRAF-mutant cancers.
  • To investigate the role of the RhoJ signaling pathway in melanoma.
  • To evaluate the efficacy of targeting RhoJ in BRAF-mutant melanoma.

Main Methods:

  • Genetic deletion of RhoJ in BRAF-mutant melanocytes.
  • Analysis of gene expression related to apoptosis and cellular metabolism.
  • Treatment of melanoma tumors with PAK inhibitors in vivo and in vitro.
  • Assessment of tumor growth, apoptosis, and signaling pathway modulation.

Main Results:

  • RhoJ deletion in BRAF-mutant cells alters expression of the pro-apoptotic protein BAD and metabolic genes.
  • This modulation impairs nevus formation, cellular transformation, and metastasis.
  • PAK inhibitors targeting RhoJ signaling halt BRAF-mutant melanoma growth in vivo.
  • Inhibition induces apoptosis via a BAD-dependent mechanism in melanoma cells.

Conclusions:

  • The RhoJ-BAD signaling network represents a therapeutic vulnerability in BRAF-mutant melanoma.
  • Targeting RhoJ offers a selective therapeutic strategy for nascent BRAF-mutant melanomas.
  • Up to 50% of BRAF-mutant melanomas show high RhoJ expression, indicating broad applicability.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.8K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.6K

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.8K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K